GALT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Galectin Therapeutics Inc (GALT) is not a strong buy for a beginner long-term investor at this time. The lack of significant positive catalysts, weak financial performance, and absence of strong trading signals suggest holding off on investment for now.
The MACD histogram is positive at 0.0953, indicating a mild bullish trend, but it is contracting. RSI is neutral at 65.988, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 2.966, with resistance at 3.233 and support at 2.699.
Analyst Matthew Keller from H.C. Wainwright raised the price target to $11 from $6, citing confidence in the company's metabolic dysfunction-associated steatohepatitis program.
No recent news or significant insider/hedge fund activity. The stock also experienced a pre-market decline of -4.66% and a regular market decline of -2.48%.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$8.22M (-26.83% YoY), and a drop in EPS to -0.13 (-27.78% YoY). Gross margin remained at 0%.
H.C. Wainwright analyst Matthew Keller maintains a Buy rating and raised the price target to $11 from $6, citing confidence in the company's metabolic dysfunction-associated steatohepatitis program.
